Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Y Hong

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Chemical Science|October 20, 2021
Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1Yuefan Wang, Hanjing Peng, Zufeng Guo, et al.
Chemico-Biological Interactions|May 31, 2011
Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1Wei Qu, Lida Cheng, Anna L Dill, et al.
Organic Letters|December 4, 2009
Glycosylated PROLI/NO derivatives as nitric oxide prodrugsRahul S Nandurdikar, Anna E Maciag, Sam Y Hong, et al.
Organic Letters|September 4, 2010
"Click" reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donorsOyebola A Oladeinde, Sam Y Hong, Ryan J Holland, et al.
Molecular Pharmaceutics|December 17, 2009
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticlesVarun Kumar, Sam Y Hong, Anna E Maciag, et al.
ACS Medicinal Chemistry Letters|January 8, 2011
The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of ProlineSam Y Hong, Gregory L Borchert, Anna E Maciag, et al.
ACS Chemical Biology|January 21, 2017
Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and AngiogenesisSarah A Head, Wei Q Shi, Eun Ju Yang, et al.
Journal of Medicinal Chemistry|October 19, 2011
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugsAnna E Maciag, Rahul S Nandurdikar, Sam Y Hong, et al.
Nature Chemistry|December 12, 2018
Rapamycin-inspired macrocycles with new target specificityZufeng Guo, Sam Y Hong, Jingxin Wang, et al.
Angewandte Chemie (International Ed. in English)|October 9, 2019
Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D MicroarraysZufeng Guo, Zhiqiang Cheng, Jingxin Wang, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Chemical Science|October 20, 2021
Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1Yuefan Wang, Hanjing Peng, Zufeng Guo, et al.
Chemico-Biological Interactions|May 31, 2011
Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1Wei Qu, Lida Cheng, Anna L Dill, et al.
Organic Letters|December 4, 2009
Glycosylated PROLI/NO derivatives as nitric oxide prodrugsRahul S Nandurdikar, Anna E Maciag, Sam Y Hong, et al.
Organic Letters|September 4, 2010
"Click" reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donorsOyebola A Oladeinde, Sam Y Hong, Ryan J Holland, et al.
Molecular Pharmaceutics|December 17, 2009
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticlesVarun Kumar, Sam Y Hong, Anna E Maciag, et al.
ACS Medicinal Chemistry Letters|January 8, 2011
The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of ProlineSam Y Hong, Gregory L Borchert, Anna E Maciag, et al.
ACS Chemical Biology|January 21, 2017
Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and AngiogenesisSarah A Head, Wei Q Shi, Eun Ju Yang, et al.
Journal of Medicinal Chemistry|October 19, 2011
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugsAnna E Maciag, Rahul S Nandurdikar, Sam Y Hong, et al.
Nature Chemistry|December 12, 2018
Rapamycin-inspired macrocycles with new target specificityZufeng Guo, Sam Y Hong, Jingxin Wang, et al.
Angewandte Chemie (International Ed. in English)|October 9, 2019
Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D MicroarraysZufeng Guo, Zhiqiang Cheng, Jingxin Wang, et al.
Pageof 2